NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT00004095 2017-04-18Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid TumorsNorthwestern UniversityPhase 1 Completed38 enrolled
NCT00031681 2013-09-307-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)National Cancer Institute (NCI)Phase 1 Completed41 enrolled